Table 1.
Characteristics of 18 Case Patients, Clinic A
| Characteristic | Cases |
|---|---|
| Male sex, n (%) | 9 (50) |
| Age, median (range), y | 63.5 (37–86) |
| Black race, n (%) | 18 (100) |
| History of diabetes, n (%)a | 9 (50) |
| History of hypertension, n (%) | 14 (78) |
| Time from first hemodialysis to seroconversion, median (range), months | 37.8 (5.6–220.1) |
| Symptoms of acute HCV infection, n (%) | 3 (17) |
| Highest documented ALT, median (range), IU/mLb | 183 (51–535) |
| During exposure period | |
| Most common treatment pod | |
| Pod 1, n (%) | 18 (100) |
| Most common treatment shift | |
| Shift 3, n (%) | 10 (56) |
| Heparin injection, n (%) | 11 (61) |
| Iron sucrose injection, n (%) | 8 (44) |
| Paricalcitol injection, n (%) | 14 (78) |
| Erythropoietin injection, n (%) | 14 (78) |
| CVC used for hemodialysis vascular access, n (%) | 3 (17) |
| History of intravenous use, n (%) | 0 (0) |
| Hospitalized or had hospital visit, n (%) | 14 (78) |
| Had invasive procedure, n (%) | 10 (56) |
| Other risk factors identified through interview (n =12) | |
| Close contact of confirmed or presumptive case, n (%) | 1 (8) |
| Received blood products, organs, or tissues, n (%) | 3 (25) |
| Exposure to another person’s blood, n (%) | 0 (0) |
| Sexual contact, n (%) | 5 (42) |
| Sexual contact without condoms, n (%) | 3 (25) |
| Injecting drugs, n (%) | 0 (0) |
| Tattoo, piercing, n (%) | 0 (0) |
NOTE. ALT, alanine aminotransferase; CVC, central venous catheter; HCV, hepatitis C virus.
a
Glucose meter use was observed and found to be adequate.
b
2 case patients did not have documented elevation of ALT.